Skip to main content
OpenTrials
Completed

NCT Number: NCT00913497

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 year–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Helen DeVos Childrens Hospital

Grand Rapids, Michigan, 49503, United States

About this study

This is a treatment, open label, crossover study comparing two and four hour breakfast post prandial blood glucose levels after receiving a dose of insulin glulisine or insulin aspart administered subcutaneously and consuming the breakfast meal from a prescribed menu containing 45, 60 or 75 grams of carbohydrate. Each subject will receive insulin glulisine for ten days and insulin aspart for ten days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • current patient in the Helen DeVos Children's Hospital Diabetes Clinic;
  • ages 4-11 years;
  • prepubertal (Tanner Stage I);
  • diagnosed with type 1 diabetes mellitus with positive islet cell antibodies or presenting at time of diagnosis with positive serum or urine ketones and requiring insulin since diagnosis;
  • at least six months from date of diagnosis of type 1 diabetes mellitus;
  • TSH within reference range and negative transglutaminase IgA antibodies within nine months of study start;
  • HbA1C between 6.9 and 10% within 30 days of study start; parent or guardian able and willing to provide written informed consent prior to enrollment;
  • at time of study start, current insulin regimen includes multiple daily injections with insulin glargine as the basal insulin and insulin aspart or insulin lispro as the pre-meal rapid acting insulin

Exclusion criteria

  • pubertal (Tanner stage 2 or greater);
  • concurrent Addison's disease, celiac disease or untreated hypothyroidism; - receiving oral, injectable or inhaled steroids or immunosuppressant medications;
  • receiving stimulants for treatment of attention deficit disorder or attention deficit hyperactivity disorder;
  • intercurrent illnesses such as a fever > 101 degrees F, infection, or gastroenteritis;
  • use of any medication to treat diabetes other than those listed under in inclusion criteria;
  • potential for lack of compliance or any other issue which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study

Treatment and study plan

insulin glulisine

Drug

Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days

Other names: (Apidra®)

insulin aspart

Drug

Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.

Other names: (NovoLog®)

Primary outcomes

  1. Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty Study Days

    Time frame: measured daily at baseline, 2 and 4 hours post prandial for 20 days

    Compare average blood glucose at 2 and 4 hours post prandial minus blood glucose at baseline (prior to eating)

Secondary outcomes

  1. Occurrence of Hypoglycemia;

    Time frame: measured daily at 2 and 4 hours postprandial for 20 days

Sponsors and collaborators

Lead sponsor

Corewell Health West

Other

Collaborators

  • Helen DeVos Children's Hospital

Registry information

Official study title

Phase 4 Crossover Study Comparing the Effect of Insulin Glulisine to Insulin Aspart on Breakfast Post Prandial Blood Glucose Levels in Prepubertal Children With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Jun 4, 2009
Registry last updated
Sep 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.